TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07259980: A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Biogen · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 125 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07259980 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07259980 Rescue Dossier →